Abstracts tagged "Crystal-induced arthritis"

Abstract Number: 1123 • ACR Convergence 2025
Nanoencapsulated Sirolimus plus Pegadricase (NASP) Demonstrates Long Term Efficacy and Safety in Patients with Uncontrolled Gout: Results from the 24-week Double-blind Extension of the Phase 3 DISSOLVE I Study
Alan Kivitz¹, Atul Singhal², Anand Patel³, Rehan Azeem⁴, Ben Peace⁵, Bhavisha Desai⁶ and Herbert Baraf⁷, ¹Altoona Center for Clinical Research, Duncansville, PA, ²SouthWest Arthritis Research Group, Mesquite, TX, ³Conquest Research, Winter Park, FL, USA, Winter Park, FL, ⁴Global MACD, Sobi Inc., Waltham, MA, ⁵Statistical Science, Sobi, Stockholm, Sweden, ⁶Sobi, Glastonbury, CT, ⁷The Center for Rheumatology and Bone Research, Rheumatology, Wheaton, Maryland, USA; Division of Rheumatology, The George Washington University, Washington, DC
Background/Purpose: Uncontrolled gout (UG) occurs when serum uric acid (sUA) levels remain persistently elevated despite use of oral urate-lowering therapies and can result in progressively…
Abstract Number: 2013 • ACR Convergence 2025
Efficacy and Safety of Firsekibart in Acute Gouty Arthritis Patients with Limited Treatment Options: A Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled Phase III Trial
Yu Xue¹, Tianshu Chu², Jiankang Hu³, Wei Gou⁴, Ning Zhang⁵, Juan Li⁶, Jing Yu⁷, Rongping Li⁸, Rongbin Li⁹, Long Qian¹⁰, Xinwang Duan¹¹, Lihua Duan¹² and Hejian Zou¹, ¹Department of Rheumatology,Huashan Hospital, Fudan University, Shanghai, China, shanghai, China (People's Republic), ²Department of Rheumatology, Henan Provincial People's Hospital, Zhengzhou, China, zhengzhou, China (People's Republic), ³Department of Rheumatology, Pingxiang People's Hospital, Pingxiang,China,, Pingxiang, China (People's Republic), ⁴Department of Rheumatology, Hebei Petro ChinaCentral Hospital, Langfang, China, Langfang, China (People's Republic), ⁵Department of Rheumatology, Shengjing Hospital of China Medical University, Shenyang, China, Shengjing, China (People's Republic), ⁶The First Affiliated Hospital of Hainan Medical University, Haikou, China (People's Republic), ⁷Department of Rheumatology, The FirstAffiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, China, Shenyang, China (People's Republic), ⁸Department of Rheumatology, The First Affiliated Hospital of GannanMedical University, Ganzhou, China, Ganzhou, China (People's Republic), ⁹Department ofRheumatology, The First Hospital of Qiqihar, Qiqihar, China, Qiqihar, China (People's Republic), ¹⁰Department of Rheumatology, The Second Hopital of Anhui Medical University, Hefei, China, Hefei, China (People's Republic), ¹¹The Second Affiliated Hospital of Nanchang University, Nanchang, China (People's Republic), ¹²Department of Rheumatology, Jiangxi Provincial People's Hospital, Nanchang, China, Nanchang, China (People's Republic)
Background/Purpose: Acute gouty arthritis(GA) is a common and debilitating condition, especially for patients unsuitable for standard therapy. Firsekibart, previously called Genakumab, is a first-in-class fully…
Abstract Number: 1101 • ACR Convergence 2025
Distinct Clinical Phenotypes of Immune Checkpoint Inhibitor–Associated Arthritis: Comparative Analysis of Inflammatory Arthritis, Polymyalgia Rheumatica-like, Activated Crystalline, and Activated Osteoarthritis
Heba Altarawneh¹, Gregory Challener², Mazen Nasrallah³, Janeth Yinh⁴, Hyon K. Choi⁵ and Minna Kohler⁶, ¹Mass General Hospital, Boston, MA, ²MGH, Boston, MA, ³MGB-Salem Hospital, Lynn, MA, ⁴Massachusetts General Hospital, Boston, MA, ⁵MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA, ⁶Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Immune checkpoint inhibitor (ICI)–associated arthritis has been classified into distinct phenotypes, including inflammatory arthritis (IA), polymyalgia rheumatica (PMR)-like syndrome, activated crystalline arthritis, and activated…
Abstract Number: 2012 • ACR Convergence 2025
A Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of ABP-671 in Subjects with Hyperuricemia or Gout in China
ullrich schwertschlag¹, yan yang², Jingfei li³, Roy Wu⁴, adam jin² and William Shi⁵, ¹Atom Therapeutics, PALO ALTO, CA, ²Atom Therapeutics, Suzhou, China (People's Republic), ³Atom Therapeutics, Suzhou, Jiangsu, China (People's Republic), ⁴Atom Bioscience, San Francisco, CA, ⁵Atom Therapeutics, Newark, CA
Background/Purpose: ABP-671 is a novel, selective and potent URAT1 inhibitor in development for the treatment of elevated serum uric acid (sUA) levels and gout.Methods: Subjects…
Abstract Number: 0231 • ACR Convergence 2025
A Quality Improvement Project to Explore the Implications of the 2020 ACR Gout Guideline Recommendations for HLA-B5801 Testing
Sarah Anstett¹, Brian Coburn², Carlos Garcia-Gonzalez³, Max Krall¹, Akash Gupta⁴, Riya Madan⁵, Stephanie Lee⁶, Tania Aguila¹, Adam Mayer⁷, Elise Breed², Preethi Thomas⁸, Nora Sandorfi¹, Anupama Shahane¹ and Rachel Dayno¹, ¹University of Pennsylvania, Philadelphia, PA, ²Hospital of the University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, ⁴Hospital of University of Pennsylvania, Philadelphia, PA, ⁵University of Pennsylvania Medical Center, Philadelphia, PA, ⁶University of Pennsylvania and Children's Hospital of Philadelphia, Philadelphia, PA, ⁷University of Pennsylvania/Children's Hospital of Philadelphia, Philadelphia, PA, ⁸UNIVERSITY OF PENNSYLVANIA, Conshohocken, PA
Background/Purpose: The presence of the HLA-B5801 allele increases the risk of life-threatening allopurinol hypersensitivity syndrome (AHS). The 2020 ACR gout management guidelines conditionally recommend HLA-B5801…
Abstract Number: 2002 • ACR Convergence 2025
Methods to Address Survival Bias and Competing Risks in Estimating the Causal Risks of Gout on Dementia Risk
Joshua Baker¹, Harlan Sayles², Chung-Chou Chang³, Brian Coburn⁴, Bryant England² and Ted Mikuls², ¹University of Pennsylvania, Philadelphia, PA, ²University of Nebraska Medical Center, Omaha, NE, ³University of Pittsburgh, Pittsburgh, PA, ⁴Hospital of the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Informative censoring in epidemiologic research studies (the loss of data from the risk set that is related to the exposure and/or outcome) can cause…
Abstract Number: 1083 • ACR Convergence 2024
Comparison of a Handheld Ultrasound Device with Cart-Based Ultrasound for the Assessment of Gout Lesions in People with Established Gout
Rachel Murdoch¹, Lene Terslev², Julia Martin³, Borislav Mihov¹, Gregory Gamble¹, Søren Torp-Pedersen⁴, Anne Horne¹ and Nicola Dalbeth¹, ¹University of Auckland, Auckland, New Zealand, ²Rigshospitalet-Glostrup & COPECARE, Glostrup, Denmark, ³Te Whatu Ora Te Toka Tumai, Auckland, New Zealand, ⁴Rigshospitalet, Copenhagen, Denmark
Background/Purpose: Ultrasound is frequently used in rheumatology practice to assist with the diagnosis of rheumatic and musculoskeletal diseases. In patients with gout, it allows visualization…
Abstract Number: 1092 • ACR Convergence 2024
Chronic Kidney Disease Is Associated with Increased Glucose Uptake-associated Metabolic Activity of Visceral Adipose and Subcutaneous Adipose Tissue in Gout Patients
Shunya Kaneshita¹, Sho Fukui², Soheil Niku³, KWANGHOON LEE⁴, Ernest Belezzuoli³, Robert Terkeltaub⁵ and Monica Guma⁶, ¹UCSD, Miyazu city, Kyoto, Japan, ²Brigham and Women's Hospital, Brookline, MA, ³UCSD, La Jolla, ⁴UCSD, San Diego, CA, ⁵Retired, San Diego, CA, ⁶UCSD, La Jolla, CA
Background/Purpose: Gout, a condition characterized by elevated uric acid levels, is linked to multiple complications, including coronary artery disease, hypertension, and type 2 diabetes mellitus.…
Abstract Number: 1094 • ACR Convergence 2024
Longitudinal Analysis of Serum Urate in Prediabetic Phase
Javier Marrugo¹, Leah Santacroce¹, Misti Paudel², Sho Fukui³, Sara Tedeschi¹ and Daniel Solomon⁴, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ³Brigham and Women's Hospital, Brookline, MA, ⁴Brigham and Women's Hospital, Newton, MA
Background/Purpose: More than 460 million people worldwide are currently living with prediabetes, a condition that not only predisposes individuals to diabetes (DM) but also to…
Abstract Number: 1095 • ACR Convergence 2024
The Incidence of Gout Among Individuals with Hyperuricemia over Time – an Insight from a Nationwide Cohort Study
Shay Brikman¹, Amir Bieber², Liel Serfaty, MA³, Ran Abuhasira, MD, PhD⁴, Nadav Rappoport⁵ and Naomi Schlesinger⁶, ¹Emek Medical Center, Afula, Israel, ²Emek Medical Center, Clalit Health Services, Raanana, Israel, ³Department of Software and Information Systems Engineering, Ben-Gurion University of the Negev, Be'er Sheva, Israel, ⁴Clinical Research Center, Soroka University Medical Center, Be'er Sheva, Israel, ⁵Ben-Gurion University of the Negev, Beer-Sheva, Israel, ⁶University of Utah, Salt Lake City, UT
Background/Purpose: Hyperuricemia is considered the most important risk factor for developing Gout, the most common adult inflammatory arthritis. Hyperuricemia is defined by a serum urate…
Abstract Number: 1103 • ACR Convergence 2024
The Role of Renal Dual-Energy CT in Exploring the Gouty Kidney: The RENODECT Study
Tristan Pascart¹, Elie Dauphin¹, Chio Yokose², Charlotte Jauffret³, Hyon K. Choi⁴ and Jean-François Budzik⁵, ¹Université Catholique de Lille, Lille, Nord-Pas-de-Calais, France, ²Massachusetts General Hospital, Boston, MA, ³Lille Catholic University, Lille, Nord-Pas-de-Calais, France, ⁴Massachusetts General Hospital, Lexington, MA, ⁵Lille Catholic University, Lille, France
Background/Purpose: Chronic kidney disease (CKD) is a common feature in gout, and can have multiple causes, some of which are gout specific, such as gout…
Abstract Number: 0267 • ACR Convergence 2024
IL-17 Participates in the Pathogenesis of Chronic Gouty Arthritis
Hong Di¹, Xinxin Han¹, Yun Zhang² and Xuejun Zeng¹, ¹Peking Union Medical College Hospital, Beijing, China, ²Peking Union Medical College Hospital (CAMS), Beijing, China
Background/Purpose: Chronic gouty arthritis (CGA) is different from acute gouty arthritis (AGA), its main characteristics include repeated or even persistent joint symptoms, tophus and bone destruction.…
Abstract Number: 1653 • ACR Convergence 2024
Osteoarthritis Drives Inflammatory Imprinting of Synovial Fibroblasts, Exacerbating Gouty Arthritis Through m6A Modification of S100A4
ZIYI CHEN¹, Yinghui Hua² and Wenjuan Wang¹, ¹Department of Sports Medicine, Huashan Hospital,Fudan University, Shanghai, Shanghai, China (People's Republic), ²Department of Sports Medicine, Huashan Hospital,Fudan University, Shanghai, China (People's Republic)
Background/Purpose: Patients with osteoarthritis (OA) face an elevated risk of future gouty arthritis (GA). To delineate the underlying cellular and molecular mechanisms of OA-driven gout…
Abstract Number: 0270 • ACR Convergence 2024
Longitudinal Patterns of C-Reactive Protein Values in Calcium Pyrophosphate Deposition (CPPD) Disease
Muneet Gill, Hongshu Guan, Jamie Collins and Sara Tedeschi, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Calcium pyrophosphate deposition (CPPD) disease is a crystalline arthritis affecting older adults. Systemic inflammation occurs during flares of acute calcium pyrophosphate (CPP) crystal arthritis…
Abstract Number: 2013 • ACR Convergence 2024
Elevated Serum Allantoin and Allantoin/uric Acid Ratio as Indicators of Oxidative Stress in Severe Gout and Cardiovascular Comorbidities
Lenka Hasikova¹, Petr Kozlik², Kveta Kalikova³, Petr Dusek⁴, Marketa Pavlikova¹, Blanka Stiburkova⁵ and Jakub Závada⁶, ¹Institute of Rheumatology, Prague, Czech Republic; Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ²Department of Analytical Chemistry, Faculty of Science, Charles University, Prague, Czech Republic, Prague, Czech Republic, ³Department of Physical and Macromolecular Chemistry, Faculty of Science, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁴Department of Neurology and Centre of Clinical Neuroscience and Department of Radiology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic, Prague, Czech Republic, ⁵Institute of Rheumatology, Prague, Czech Republic and Department of Paediatrics and Inherited Metabolic Disorders, 1st Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic, Prague, Czech Republic, ⁶Institute of Rheumatology and Charles University, Praha, Czech Republic
Background/Purpose: Uric acid (UA) can be non-enzymatically oxidized into allantoin and other products by reactive oxygen species under conditions of increased oxidative stress. Consequently, allantoin…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].